![Surviving-an-FDA-GCP-Inspection-500.jpg Surviving an FDA GCP Inspection](https://www.centerwatch.com/ext/resources/products/Surviving-an-FDA-GCP-Inspection-500.jpg?height=200&t=1605810958&width=200)
Home » More than a Third of U.S., European Trial Professionals View Digitalization as Good
More than a Third of U.S., European Trial Professionals View Digitalization as Good
December 20, 2021
More than one-third of trial professionals based in the U.S. and Europe believe that digitalization, including the use of real-world evidence, is making trials better, a new survey shows.
Specifically, 39 percent of U.S. and European trial professionals felt that the digitalization of clinical and preclinical trials is improving them, according to a recent GlobalData survey of 131 respondents.
By contrast, only 28 percent of respondents in the Asia-Pacific region think digitalization, which entails the use of emerging technologies, such as artificial intelligence (AI), real-world evidence, application programming interfaces (APIs) and digital platforms, improves trials. This year’s survey results were in line with those seen in both 2019 and 2020, GlobalData said.
![To view more CenterWatch Weekly stories, click here.](https://no-cache.hubspot.com/cta/default/4532008/07345fb0-4711-43d9-b045-10bbf88744d8.png)
Upcoming Events
-
21Oct